TWP
VTVT icon

Triad Wealth Partners’s vTv Therapeutics VTVT Stock Holding History

Triad Wealth Partners’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$18 – 919
2024
Q2 		$18 Buy
+1
New +$24 ﹤0.01% 991

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCMC
Planning Capital Management Corporation Paoli, Pennsylvania $151M AUM 30.62% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Triad Wealth Partners's VTVT Position: Q3 2024 in Review

Triad Wealth Partners sold out of vTv Therapeutics (VTVT) in Q3 2024, closing a stake of 1 share — an estimated $18 sold.

Triad Wealth Partners first reported a position in VTVT in Q2 2024 and held it in 1 quarter. The position peaked at $18 in Q2 2024. 20 funds tracked by Wall St. Rank hold VTVT as of Q3 2024.

  • Triad Wealth Partners reported no remaining vTv Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Triad Wealth Partners sold 1 vTv Therapeutics share in Q3 2024, an estimated $18.
  • Triad Wealth Partners first reported a position in vTv Therapeutics in Q2 2024 and held it in 1 quarter.
  • Triad Wealth Partners's vTv Therapeutics position peaked at $18 in Q2 2024.
  • 20 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2024.

Based on Triad Wealth Partners's 13F filing for Q3 2024, filed 21 Oct 2024.